FDA Panel Recommends EUA for Novavax COVID-19 Vaccine
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19…
CONTINUE READINGGuillain-Barré Syndrome Linked to COVID-19 Shots
A study by the University College London showed that serious Guillain-Barré syndrome (GBS), which can result in temporary or permanent…
Pfizer, Moderna Apply for EUA for COVID Shots for Infants, FDA to Decide Quickly
On June 1, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA) for an…
COVID Vaccine-Induced Cardiovascular Events Raise Concerns for Adolescents and Young Adults
A new study published in the peer-reviewed journal Nature found significantly more emergency heart events in adults under 40 that…
Pfizer and Moderna COVID-19 Shots Can Trigger Alopecia Areata in Patients with Autoimmune Conditions
Following the granting by the U.S. Food and Drug Administration (FDA) of Emergency Use Authorization (EUA) status for Pfizer/BioNTech’s BNT162b2…
Moderna Recalls 764,900 Doses of Spikevax Due to Contamination Problem
Moderna, Inc., developer of the experimental messenger RNA (mRNA) mRNA-1273, or “Spikevax,” biologic, has recalled 764,900 doses in lot #000190A…
FDA Approves Fourth COVID Shot. Fifth Shot Considered.
On Mar. 29, 2022, the U.S. Food and Drug Administration (FDA) approved a second booster dose (a fourth shot) of…